Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Sells $97,950.72 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the sale, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at approximately $10,993,400.32. The trade was a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Markus Warmuth also recently made the following trade(s):

• On Wednesday, January 7th, Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $23.49, for a total value of $128,396.34.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ GLUE opened at $17.80 on Friday. The business’s 50-day simple moving average is $19.99 and its 200-day simple moving average is $14.02. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.50 and a 52 week high of $25.77. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 55.63 and a beta of 1.63.

Analyst Upgrades and Downgrades

GLUE has been the subject of a number of analyst reports. Wells Fargo & Company boosted their price objective on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Jefferies Financial Group restated a “buy” rating and issued a $31.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Zacks Research cut shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 4th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Finally, Guggenheim lifted their price target on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its stake in Monte Rosa Therapeutics by 10.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after buying an additional 481,844 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Monte Rosa Therapeutics by 8.6% during the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after buying an additional 257,547 shares during the period. State Street Corp grew its holdings in shares of Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after buying an additional 1,260,707 shares in the last quarter. AQR Capital Management LLC raised its position in Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after buying an additional 1,054,406 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Monte Rosa Therapeutics by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after acquiring an additional 53,278 shares during the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.